---
title: "Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Indication questions"
description: "Indication questions on Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Drug names and Testing. Questions: What is Vyndamax approved for? What is the generic name of Vyndamax? What drug class is Vyndamax? What is the difference between Vyndamax and Vyndaqel? 9 further questions follow. 13 questions quoted from 4 sources."
canonical: "https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/indication"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vyndamax (tafamidis) in transthyretin amyloid cardiomyopathy: Indication questions

Manufacturer: Pfizer Inc  
Prescribing information: [Vyndaqel and Vyndamax](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685)

## Indication

<a id="vyndamax-indication"></a>

### What is Vyndamax approved for?

> “VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20and%20VYNDAMAX%20are%20indicated,cardiovascular%20mortality%20and%20cardiovascular%2Drelated%20hospitalization.)

<a id="vyndamax-attr-cm-overview"></a>

### What is ATTR-CM, the disease Vyndamax treats?

> “ATTR cardiac amyloidosis is a progressive, fatal disease that requires early identification and intervention<sup>1,2</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=ATTR%20cardiac%20amyloidosis%20is%20a,that%20requires%20early%20identification%20and)

> “There are 2 subtypes of ATTR cardiac amyloidosis<sup>1</sup>
> Wild-type ATTR cardiac amyloidosis (wtATTR cardiac amyloidosis)
> Presents most commonly in older white men, >60 years of age<sup>11-13</sup>
> Prevalence increases with age<sup>14</sup>
> Hereditary ATTR cardiac amyloidosis (hATTR cardiac amyloidosis)<sup>†</sup>
> Affects both men and women<sup>15,16</sup>
> May occur as early as 50 to 60 years of age<sup>17</sup>
> Onset varies according to mutation<sup>17</sup>
> The most common variant in the United States, Val122lle, is carried by ~3%-4% of African Americans<sup>16</sup><sup>‡</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=There%20are%202%20subtypes%20of,carried%20by%20~3%25%2D4%25%20of%20African)

> “In the United States, Val122lle and Thr60AIa are the most common mutations that typically manifest as cardiomyopathy symptoms.<sup>15</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=In%20the%20United%20States%2C%20Val122lle%20and,that%20typically%20manifest%20as%20cardiomyopathy)

> “Not all individuals with the V122I mutation develop symptoms.<sup>16</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=Not%20all%20individuals%20with%20the%20V122I%20mutation%20develop)

> “ATTR=transthyretin amyloidosis; ATTR-CM=transthyretin amyloid cardiomyopathy”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=ATTR%3Dtransthyretin%20amyloidosis%3B%20ATTR%2DCM%3Dtransthyretin%20amyloid%20cardiomyopathy)

<a id="vyndamax-attr-cm-untreated-survival"></a>

### What is life expectancy with untreated ATTR-CM, the disease Vyndamax treats?

> “If not treated, patients with ATTR-CM have an estimated median survival of ~2-6 years after diagnosis<sup>5,6</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=If%20not%20treated%2C%20patients%20with,survival%20of%20~2%2D6%20years%20after)

Note: The Understanding ATTR-CM page of the Vyndamax HCP site cites Maurer et al., Circ Heart Fail 2019, and Gillmore et al., Eur Heart J 2018, for this estimate.

## Drug names

<a id="vyndamax-generic-name"></a>

### What is the generic name of Vyndamax?

> “VYNDAMAX™ (tafamidis) capsules, for oral administration”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAMAX%E2%84%A2%20%28tafamidis%29%20capsules%2C%20for%20oral%20administration)

> “VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) contain tafamidis as the active moiety, which is a selective stabilizer of transthyretin.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20%28tafamidis%20meglumine%29%20and%20VYNDAMAX,a%20selective%20stabilizer%20of%20transthyretin.)

<a id="vyndamax-drug-class"></a>

### What drug class is Vyndamax?

> “VYNDAQEL and VYNDAMAX are transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20and%20VYNDAMAX%20are%20transthyretin,cardiovascular%20mortality%20and%20cardiovascular%2Drelated%20hospitalization.)

<a id="vyndamax-vs-vyndaqel"></a>

### What is the difference between Vyndamax and Vyndaqel?

> “VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) contain tafamidis as the active moiety, which is a selective stabilizer of transthyretin.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20%28tafamidis%20meglumine%29%20and%20VYNDAMAX,a%20selective%20stabilizer%20of%20transthyretin.)

> “VYNDAQEL is available as:
>
> •
> tafamidis meglumine 20 mg: yellow, opaque, oblong capsule, printed with "VYN 20" in red.
>
> VYNDAMAX is available as:
>
> •
> tafamidis 61 mg: reddish brown, opaque, oblong capsule, printed with "VYN 61" in white.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=VYNDAQEL%20is%20available%20as%3A,with%20%22VYN%2061%22%20in%20white.)

> “The recommended dosage is either VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily or VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily.”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=The%20recommended%20dosage%20is%20either%20VYNDAQEL,tafamidis%20capsule%29%20orally%20once%20daily.)

> “VYNDAMAX and VYNDAQEL are not substitutable on a per mg basis [see Clinical Pharmacology (12.3)].”

Source: [VYNDAMAX: Prescribing information, captured 2026-11-13](https://labeling.pfizer.com/ShowLabeling.aspx?id=11685#:~:text=orally%20once%20daily.-,VYNDAMAX%20and%20VYNDAQEL%20are%20not%20substitutable%20on%20a%20per%20mg,basis%20%5Bsee%20Clinical%20Pharmacology%20%2812.3%29%5D.)

## Testing

<a id="vyndamax-attr-cm-misdiagnosis"></a>

### Is ATTR-CM, the disease Vyndamax treats, often misdiagnosed or diagnosed late?

> “Some patients may take >5 years to be diagnosed with ATTR-CM<sup>4</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=Some%20patients%20may%20take%20%3E5%20years%20to%20be%20diagnosed%20with)

> “More than 33% of patients with ATTR-CM are misdiagnosed<sup>7</sup>”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=More%20than%2033%25%20of%20patients%20with%20ATTR%2DCM%20are)

Note: The Understanding ATTR-CM page of the Vyndamax HCP site cites Nakagawa et al., Amyloid 2016, for the diagnostic delay and Rozenbaum et al., Cardiol Ther 2021, a targeted literature review, for the misdiagnosis figure.

<a id="vyndamax-attr-cm-red-flags"></a>

### What are the red flags of ATTR-CM, the disease Vyndamax treats?

> “Identifying these red flags, especially in combination, is key to early screening and diagnosis of ATTR-CM<sup>1</sup>”

Source: [VYNDAMAX: Red Flags of ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/red-flags-of-attr-cm#:~:text=Identifying%20these%20red%20flags%2C%20especially,early%20screening%20and%20diagnosis%20of)

> “Other red flags of ATTR-CM:
>   Clinical history<sup>1,3</sup>	  
> Imaging results<sup>1,5,9</sup>
>
> Bilateral carpal tunnel syndrome
> Refractory to standard HF therapies (GDMT)
> Severe aortic stenosis
> Lumbar spinal stenosis
> Autonomic or sensory PN
>
> Discordance between LV wall thickness and QRS voltage on ECG
> Dilated left atrium or bi-atrial enlargement
>
> While these patient characteristics may be suggestive of ATTR-CM, they are not exhaustive.”

Source: [VYNDAMAX: Red Flags of ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/red-flags-of-attr-cm#:~:text=Other%20red%20flags%20of%20ATTR%2DCM%3A,ATTR%2DCM%2C%20they%20are%20not%20exhaustive.)

<a id="vyndamax-attr-cm-hfpef"></a>

### How common is ATTR-CM, which Vyndamax treats, in older patients with HFpEF?

> “Did you know? ~1 in 10 patients aged >60 years with HFpEF were found to have ATTR-CM<sup>2</sup>”

Source: [VYNDAMAX: Red Flags of ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/red-flags-of-attr-cm#:~:text=Did%20you%20know%3F%20~1%20in,HFpEF%20were%20found%20to%20have)

> “Study design: The study by González-López, et al was a prospective, cross-sectional, single-center study at a tertiary university hospital in Madrid, Spain, to determine the prevalence of wtATTR-CM among elderly patients admitted to the hospital due to HFpEF. The study population included 120 HFpEF patients (59% women, mean age: 82±8 years) with LV ejection fraction ≥50% and LV hypertrophy ≥12 mm. All eligible patients were offered a DPD scintigraphy scan to confirm ATTR cardiac amyloidosis.”

Source: [VYNDAMAX: About ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/understanding-attr-cm#:~:text=Study%20design%3A%20The%20study%20by,to%20confirm%20ATTR%20cardiac%20amyloidosis.)

Note: The red flags page cites González-López et al., Eur Heart J 2015, for the first figure; the study design passage is from the Understanding ATTR-CM page of the Vyndamax HCP site.

<a id="vyndamax-attr-cm-carpal-tunnel"></a>

### How common is carpal tunnel syndrome in ATTR amyloidosis, including ATTR-CM, which Vyndamax treats?

> “In observational studies of ATTR amyloidosis populations, including ATTR cardiomyopathy, between 29% (n=16/55) and 68% (n=21/31) of patients have been reported to have a history of carpal tunnel syndrome”

Source: [VYNDAMAX: Red Flags of ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/red-flags-of-attr-cm#:~:text=In%20observational%20studies%20of%20ATTR,history%20of%20carpal%20tunnel%20syndrome)

<a id="vyndamax-attr-cm-echocardiogram"></a>

### What echocardiogram findings suggest ATTR-CM, the disease Vyndamax treats?

> “Echocardiography suggestive of ATTR-CM
> Echocardiography<sup>3-6</sup>
> LV wall thickness ≥12 mm on an echocardiogram<sup>3-6</sup>*<sup>†</sup>
> Reduction in longitudinal strain with apical sparing<sup>5-7‡</sup>
> Apical sparing on a bullseye strain map: the lack of amyloid deposition in the apex may result in a “cherry on top” pattern, in which a red circle at the apex (preserved strain) is surrounded by lighter shades of red or blue (reduced strain)
> Changes to the interatrial septum and valves<sup>5,7‡</sup>
> Thickening of interatrial septum (yellow arrow) and valves (white arrow) >0.5 cm<sup>5,7</sup>
> Additional cardiac features to consider are<sup>5</sup>:
> Increased echogenicity of the myocardium (sparkling, hyper-refractile “texture” of the myocardium)
> Atrial enlargement and dysfunction
> Diastolic dysfunction of Grade 2 or worse with high E/A ratio (>1.5) and reduced E deceleration time (<150 ms)
> Increased pressures (>35 mmHg for PA, ≥10 mmHg for RA)
> Per the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure, a left ventricular wall thickness of ≥14 mm, along with other clinical parameters, should heighten suspicion of ATTR cardiac amyloidosis.”

Source: [VYNDAMAX: Red Flags of ATTR‑CM | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/red-flags-of-attr-cm#:~:text=Echocardiography%20suggestive%20of%20ATTR%2DCM,suspicion%20of%20ATTR%20cardiac%20amyloidosis.)

Note: The arrow references and the strain map description refer to echocardiogram images on the red flags page of the Vyndamax HCP site, which are not reproduced here.

<a id="vyndamax-attr-cm-diagnosis"></a>

### How is ATTR-CM, the disease Vyndamax treats, diagnosed?

> “To diagnose ATTR-CM, order these 2 tests concurrently<sup>1</sup>*:
> AL tests
> Tests	Serum protein electrophoresis (SPEP) with immunofixation	Urine protein electrophoresis (UPEP) with immunofixation	Serum free light chain assay
> Normal range	No M-spike present	No M-spike present	Kappa:lambda ratio=0.26-1.65†
> Electrophoresis alone is insufficient without immunofixation.<sup>2</sup>
> Kappa:lambda ratio is higher in patients with chronic kidney disease.
> AL test results interpretation 
> AL test results<sup>2,3</sup>	Diagnosis<sup>2,3</sup>
> Abnormal	AL possible—refer to a hematology specialist for evaluation
> Normal	AL unlikely—refer to cardiac amyloid radionuclide imaging results to determine if ATTR cardiac amyloidosis is possible”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=To%20diagnose%20ATTR%2DCM%2C%20order%20these,ATTR%20cardiac%20amyloidosis%20is%20possible)

> “ASNC advises utilization of <sup>99m</sup>Tc-PYP or <sup>99m</sup>Tc-HMDP tracers to diagnose ATTR cardiac amyloidosis<sup>2§</sup>”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=ASNC%20advises%20utilization%20of,tracers%20to%20diagnose%20ATTR%20cardiac)

> “<sup>99m</sup>Tc-PYP and <sup>99m</sup>Tc-HMDP are not FDA approved for the diagnosis of ATTR cardiac amyloidosis. Please consult individual labeling for risks.”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=are%20not%20FDA%20approved%20for,consult%20individual%20labeling%20for%20risks.)

> “If clinical suspicion is high despite a negative or inconclusive scan, a biopsy should be considered.<sup>2</sup>”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=If%20clinical%20suspicion%20is%20high,scan%2C%20a%20biopsy%20should%20be)

<a id="vyndamax-attr-cm-pyp-scan"></a>

### What PYP scan H/CL ratio indicates ATTR-CM, the disease Vyndamax treats?

> “H/CL ratios of ≥1.5 at 1 hour can accurately identify ATTR cardiac amyloidosis if myocardial tracer uptake is visually confirmed on SPECT and systemic AL amyloidosis is excluded. An H/CL ratio of ≥1.3 at 3 hours can identify ATTR cardiac amyloidosis”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=H%2FCL%20ratios%20of%20%E2%89%A51.5%20at,can%20identify%20ATTR%20cardiac%20amyloidosis)

> “NOTE: Diagnosis of ATTR cardiac amyloidosis cannot be made solely based on H/CL ratio alone. H/CL ratio is not recommended if there is an absence of myocardial uptake on SPECT”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=NOTE%3A%20Diagnosis%20of%20ATTR%20cardiac,of%20myocardial%20uptake%20on%20SPECT)

> “<sup>99m</sup>Tc-PYP and <sup>99m</sup>Tc-HMDP are not FDA approved for the diagnosis of ATTR cardiac amyloidosis. Please consult individual labeling for risks.”

Source: [VYNDAMAX: Diagnosing ATTR Cardiac Amyloidosis | VYNDAMAX® (tafamidis) | Safety Info, captured 2026-11-13](https://vyndamax.pfizerpro.com/about-attrcm/diagnosing-attrcm#:~:text=are%20not%20FDA%20approved%20for,consult%20individual%20labeling%20for%20risks.)

## Related pages
- [Medical information: Vyndamax (tafamidis): Transthyretin amyloid cardiomyopathy](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy)
- [Pharmacology](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/vyndamax--transthyretin-amyloid-cardiomyopathy/guidelines)
